The mirror-image form of CBD is 10 times more potent at blocking CB1 receptor signaling and activates sphingosine receptors
The synthetic enantiomer (+)-CBD was roughly 10 times more potent than natural (-)-CBD at inhibiting endocannabinoid signaling at CB1 receptors and also activated sphingosine-1-phosphate receptors, revealing a distinct pharmacological profile.
Quick Facts
What This Study Found
(+)-CBD had a 5-fold lower inhibition constant for displacing a CB1 agonist and was approximately 10 times more potent at inhibiting depolarization-induced suppression of excitation (DSE), a form of endocannabinoid-mediated synaptic plasticity. (+)-CBD also stereoselectively activated sphingosine-1-phosphate receptors S1P1 and S1P3, a completely different signaling pathway.
Key Numbers
(+)-CBD was ~5x more potent at displacing CP55,940 at CB1 and ~10x more potent at inhibiting DSE compared to (-)-CBD.
How They Did This
Enantioselective synthesis of both CBD enantiomers, with a new NMR-based method for confirming enantiomeric purity. Pharmacological testing in autaptic hippocampal neurons (a model of endocannabinoid signaling) and CHO-K1 cells. Binding, signaling, and functional assays performed.
Why This Research Matters
Natural cannabis only produces (-)-CBD, but the synthetic mirror image (+)-CBD has dramatically different pharmacology, suggesting that CBD's 3D shape matters enormously for its biological effects and opening new drug development possibilities.
The Bigger Picture
The discovery that CBD enantiomers have distinct signaling profiles, including activation of sphingosine-1-phosphate receptors by (+)-CBD, expands the potential therapeutic toolkit derived from cannabis chemistry beyond what the plant naturally produces.
What This Study Doesn't Tell Us
In vitro and cell-based studies only. (+)-CBD does not occur naturally and its in vivo effects are unknown. The clinical significance of S1P receptor activation by (+)-CBD is unclear. No behavioral or therapeutic testing performed.
Questions This Raises
- ?Could (+)-CBD be a more effective CB1 modulator than natural CBD?
- ?What therapeutic applications might arise from its S1P receptor activation?
- ?Would it have the same safety profile as natural CBD?
Trust & Context
- Key Stat:
- (+)-CBD is 10x more potent at CB1 than natural (-)-CBD
- Evidence Grade:
- Rigorous in vitro pharmacology with novel synthetic compounds, but no in vivo or clinical data.
- Study Age:
- Published in 2022.
- Original Title:
- Differential Enantiomer-Specific Signaling of Cannabidiol at CB1 Receptors.
- Published In:
- Molecular pharmacology, 102(6), 259-268 (2022)
- Authors:
- Bosquez-Berger, Taryn, Wilson, Sierra, Iliopoulos-Tsoutsouvas, Christos(2), Jiang, Shan, Wager-Miller, Jim, Nikas, Spyros P, Mackie, Ken P, Makriyannis, Alexandros, Straiker, Alex
- Database ID:
- RTHC-03724
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is an enantiomer?
Enantiomers are mirror-image versions of the same molecule, like left and right hands. Natural cannabis produces only (-)-CBD, but the mirror-image (+)-CBD can be synthesized in the lab and has different biological properties.
Why is (+)-CBD more potent than natural CBD?
The 3D shape of a molecule determines how it fits into receptors. (+)-CBD's mirror-image shape apparently fits CB1 receptors more snugly, resulting in about 10 times greater potency at blocking endocannabinoid signaling.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03724APA
Bosquez-Berger, Taryn; Wilson, Sierra; Iliopoulos-Tsoutsouvas, Christos; Jiang, Shan; Wager-Miller, Jim; Nikas, Spyros P; Mackie, Ken P; Makriyannis, Alexandros; Straiker, Alex. (2022). Differential Enantiomer-Specific Signaling of Cannabidiol at CB1 Receptors.. Molecular pharmacology, 102(6), 259-268. https://doi.org/10.1124/molpharm.121.000305
MLA
Bosquez-Berger, Taryn, et al. "Differential Enantiomer-Specific Signaling of Cannabidiol at CB1 Receptors.." Molecular pharmacology, 2022. https://doi.org/10.1124/molpharm.121.000305
RethinkTHC
RethinkTHC Research Database. "Differential Enantiomer-Specific Signaling of Cannabidiol at..." RTHC-03724. Retrieved from https://rethinkthc.com/research/bosquez-berger-2022-differential-enantiomerspecific-signaling-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.